Evusheld Astrazeneca News Today

AstraZeneca has reported that its Evusheld offered protection against symptomatic Covid-19 for a minimum of six months in Phase III trial.

The Vaccine Project Newsletter: All tired out. From PR Week

British-Swedish pharmaceutical giant AstraZeneca on Tuesday said that Samsung Biologics, the biotech arm of Samsung Group, will manufacture its antibody combination against Covid-19.Under an agreement valued at approximately $380 million, ...

British-Swedish pharmaceutical giant AstraZeneca on Tuesday said that Samsung Biologics, the biotech arm of Samsung Group, will manufacture its antibody combination against Covid-19.